Richard Torres Selected Research

Proteins (Proteins, Gene)

1/2019	Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease.
1/2015	Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver.
12/2010	The major genetic determinants of HIV-1 control affect HLA class I peptide presentation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Richard Torres Research Topics

Disease

3	Inflammation (Inflammations) 01/2021 - 08/2007
2	Liver Diseases (Liver Disease) 01/2021 - 01/2021
2	Fibrosis (Cirrhosis) 01/2019 - 04/2016
2	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 07/2014
2	Neoplasms (Cancer) 01/2019 - 01/2015
2	Pain (Aches) 04/2009 - 08/2007
1	Hemophilia A (Haemophilia) 03/2022
1	Biliary Atresia 01/2021
1	Vascular Remodeling 01/2020
1	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2020
1	Papilledema 01/2020
1	Retinal Degeneration 01/2020
1	Telangiectasis (Telangiectasia) 01/2020
1	Vascular Diseases (Vascular Disease) 01/2020
1	Retinal Neovascularization 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 01/2019
1	Hematologic Neoplasms (Hematological Malignancy) 01/2019
1	Necrosis 01/2019
1	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 01/2019
1	Chronic Renal Insufficiency 01/2019
1	Cysts 10/2018
1	Hepatocellular Carcinoma (Hepatoma) 01/2015
1	Hepatitis 07/2014
1	Sialadenitis 07/2014
1	Lymphadenopathy 07/2014
1	Weight Loss (Weight Reduction) 07/2014
1	Dehydration (Water Stress) 03/2014
1	Lymphoma (Lymphomas) 12/2012
1	Arthritis (Polyarthritis) 02/2012
1	Virus Diseases (Viral Diseases) 12/2010
1	HIV Infections (HIV Infection) 12/2010
1	Hemorrhage 06/2009
1	von Willebrand Diseases (von Willebrand's Disease) 06/2009
1	Hyperalgesia 08/2007

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 01/2019 - 12/2010
2	AutoantibodiesIBA 01/2021 - 02/2012
2	von Willebrand FactorIBA 01/2020 - 06/2009
2	Peptides (Polypeptides)IBA 01/2015 - 12/2010
2	neuromedin UIBA 02/2012 - 08/2007
1	Valoctocogene RoxaparvovecIBA 03/2022
1	AutoantigensIBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	EndoglinIBA 01/2020
1	Glial Fibrillary Acidic ProteinIBA 01/2020
1	Retinaldehyde (Retinal)IBA 01/2020
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020
1	Alemtuzumab (Campath)FDA Link 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019
1	Cisplatin (Platino)FDA LinkGeneric 01/2019
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2018
1	CollagenIBA 04/2016
1	pigment epithelium-derived factorIBA 01/2015
1	Low Density Lipoprotein Receptor-Related Protein-6IBA 01/2015
1	CateninsIBA 01/2015
1	IpilimumabIBA 07/2014
1	teplizumabIBA 07/2014
1	Nucleic AcidsIBA 03/2014
1	CyclinsIBA 12/2012
1	CalciumIBA 02/2012
1	NeuropeptidesIBA 02/2012
1	HLA Antigens (Human Leukocyte Antigens)IBA 12/2010
1	Amino Acids FDA Link 12/2010
1	CytokinesIBA 04/2009
1	Interleukin-1beta (Interleukin 1 beta)IBA 04/2009
1	InflammasomesIBA 04/2009
1	Capsaicin (Zostrix)FDA Link 08/2007
1	Formaldehyde (Formol)FDA Link 08/2007
1	Freund's AdjuvantIBA 08/2007

Therapy/Procedure

2	Therapeutics 01/2021 - 01/2020